J&J-backed Bright Peak secures $90m to advance immunoconjugate programme
The funds will be used to advance PD1-IL18 immunoconjugate BPT567 into early-stage trials for solid tumours.
The funds will be used to advance PD1-IL18 immunoconjugate BPT567 into early-stage trials for solid tumours.
What's Your Reaction?
